Amylin
Amylin
Metabolic & Endocrine
Amylin is indexed as endogenous peptide hormone in the PeptideBase article library. It is referenced in “CagriSema Explained: Semaglutide, Cagrilintide, and the Amylin + GLP-1 Strategy” and 2 other PeptideBase articles. This page groups the relevant coverage; evidence strength, safety, and clinical relevance depend on the specific claim and source.
Deep Dives on Amylin
Start here for the plain-English articles connected to this peptide.
GIP Agonism vs Antagonism: Why Opposite Strategies Can Both Reduce Food Intake in Mice
A 2026 mouse study suggests GIPR agonism and antagonism can affect food intake and body weight through distinct brain regions—not interchangeable mechanisms.
Read articleCould Astronauts Make Peptide Medicines in Space? What the New Astropharmacy Study Actually Shows
A 2026 study ranked 26 peptide medicines for possible on-demand spaceflight production. Here is what the scoring shows—and what it does not prove.
Read articleCagriSema Explained: Semaglutide, Cagrilintide, and the Amylin + GLP-1 Strategy
A cautious, evidence-aware explainer on CagriSema, the investigational semaglutide plus cagrilintide combination, and why the amylin + GLP-1 strategy is not just stronger semaglutide.
Read articleQuick Facts
- Origin
- Named endogenous peptide hormone referenced in PeptideBase coverage
- Category
- Metabolic & Endocrine